Yahoo
XETRA - Delayed Quote EUR

Merck KGaA (MRK.DE)

135.85 -2.00 (-1.45%)
At close: September 4 at 5:35:30 PM GMT+2
Chart Range Bar
Loading chart for MRK.DE
  • Previous Close 137.85
  • Open 137.60
  • Bid 136.00 x --
  • Ask 136.10 x --
  • Day's Range 135.10 - 137.60
  • 52 Week Range 100.70 - 148.80
  • Volume 230,217
  • Avg. Volume 293,423
  • Market Cap (intraday) 59.065B
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) 24.93
  • EPS (TTM) 5.45
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield 2.20 (1.62%)
  • Ex-Dividend Date Apr 27, 2026
  • 1y Target Est 153.50

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

www.emdgroup.com

62,136

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

MRK.DE
13.03%
DAX P (^GDAXI)
6.35%

1-Year Return

MRK.DE
27.72%
DAX P (^GDAXI)
9.58%

3-Year Return

MRK.DE
15.18%
DAX P (^GDAXI)
64.59%

5-Year Return

MRK.DE
28.74%
DAX P (^GDAXI)
65.05%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 5.25B
Earnings 319M
Profit Margin 6.08%

Q2

FY25

Q3

FY25

Q4

FY25

0
1B
2B
3B
4B
5B
8.0%
10.0%
12.0%
14.0%
16.0%

Analyst Insights

View More

Analyst Price Targets

135.00
153.50 Average
135.85 Current
179.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.21%

  • Return on Assets (ttm)

    4.65%

  • Return on Equity (ttm)

    8.13%

  • Revenue (ttm)

    21.13B

  • Net Income Avi to Common (ttm)

    2.37B

  • Diluted EPS (ttm)

    5.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.12B

  • Total Debt/Equity (mrq)

    40.62%

  • Levered Free Cash Flow (ttm)

    2.63B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: